Combinatorial immunotherapy for melanoma.
Melanoma has been a long-standing focal point for immunotherapy development. In this review, we explore the evolution of melanoma treatments with particular attention to the history and recent advances in melanoma immunotherapy. We also discuss novel combinations of these modalities and their potential to offer novel therapeutic options for patients with advanced melanoma.
Division of Dermatology, Roger Williams Medical Center, Department of Medicine RWMC, Providence, RI, USA.
D D
DD
George
Division of Oncology, Roger Williams Medical Center, Providence, RI, USA.|Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
V A
VA
Armenio
Department of Surgery, Roger Williams Medical Center, Providence, RI, USA.|Department of Surgery, Boston University School of Medicine, Boston, MA, USA.
S C
SC
Katz
D000818:Animals; D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D003131:Combined Modality Therapy; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D008545:Melanoma / Q000209:etiology / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D050130:Oncolytic Virotherapy; D011878:Radiotherapy; D012878:Skin Neoplasms
D000074322:Antineoplastic Agents, Immunological; D014408:Biomarkers, Tumor